OverviewSuggest Edit

Molecular Partners is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of biopharmaceutical products. The Company also develops designed ankyrin repeat protein platform therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments.

TypePublic
Founded2004
HQZürich-Schlieren, CH
Websitemolecularpartners.com

Latest Updates

Employees (est.) (May 2021)145(+2%)
Share Price (Jun 2021)CHF23.7

Key People/Management at Molecular Partners

Michael Tobias Stumpp

Michael Tobias Stumpp

Chief Operating Officer and Member of the Management Board
Patrick Amstutz

Patrick Amstutz

Chief Executive Officer and Director
Andreas Emmenegger

Andreas Emmenegger

Chief Financial Officer and Member of the Management Board
Nicolas Leupin

Nicolas Leupin

Chief Medical Officer and Member of the Management Board
Ana Maria Mendes Cerdeira

Ana Maria Mendes Cerdeira

VP, Strategic Planning and Portfolio Strategy
Seth Lewis

Seth Lewis

SVP Investor Relations, Communications and Strategy
Show more

Molecular Partners Office Locations

Molecular Partners has offices in Zürich-Schlieren and Cambridge
Zürich-Schlieren, CH (HQ)
14 Wagistrasse
Cambridge, MA, US
245 Main St
Show all (2)

Molecular Partners Financials and Metrics

Molecular Partners Revenue

Market capitalization (4-Jun-2021)

690.8m

Closing stock price (4-Jun-2021)

23.7
Molecular Partners's current market capitalization is CHF690.8 m.
Show all financial metrics

Molecular Partners Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Molecular Partners Online and Social Media Presence

Embed Graph

Molecular Partners News and Updates

Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19

Basel, May 27, 2021 — Novartis and Molecular Partners announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will conduct the clinical trial program for e…

Novartis announces collaboration with Molecular Partners to develop two DARPin therapies designed for potential use against COVID-19

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19 MP0420 and MP0423 are potential medicines with a unique approach for both the …

AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin® Program

SEATTLE, July 9, 2020 /PRNewswire/ -- Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) AGC Biologics is partnering with clinical-stage biotech company Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®. AGC...

Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol

NORTH CHICAGO, Ill., June 26, 2020 /PRNewswire/ -- Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S....

Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration

DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform,...

Molecular Partners agrees cancer immunotherapy deal with Amgen

Swiss biotechnology company Molecular Partners said it could earn more than $500 million in payments after striking a deal with U.S. drug giant Amgen to work together in cancer immunotherapy.

Molecular Partners Blogs

Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol

The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation Previously reported positive Phase 3 results demonstrated the potential for abicipar to be the first anti-VEGF therapy... The post Allergan and Molecular Partners Announce Topline Safety Results…

Molecular Partners to present pre-clinical data on its FAP x CD40 multi-DARPin® molecule and on DARPin® drug conjugates (DDCs) at the AACR 2019

Molecular Partners presents new pre-clinical data at the AACR 2019, highlighting the company’s immuno-oncology and DARPin® directed drug delivery (DDC) platforms. The post Molecular Partners to present pre-clinical data on its FAP x CD40 multi-DARPin® molecule and on DARPin® drug conjugates (DDCs) a…

Molecular Partners Publishes Invitation to Annual General Meeting 2019

Molecular Partners published the invitation to the Annual General Meeting 2019. The post Molecular Partners Publishes Invitation to Annual General Meeting 2019 appeared first on Molecular Partners.

Molecular Partners Publishes Audited Financial Results for 2018 and Annual Report 2018

Zurich-Schlieren, March 15, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today published its audited Financial Results for 2018... The post Molecular Partners Publishes Audited Financial Results for 2…

MOLECULAR PARTNERS TO PRESENT AT THE COWEN AND COMPANY 39th ANNUAL HEALTHCARE CONFERENCE

In its presentation at the Cowen and Company 39th Annual Healthcare Conference, Molecular Partners highlights the progress on its clinical DARPin® compounds, discuss MP0310 in its strategic partnership with Amgen and update on the initiation of a research project to explore DARPin® molecules targeti…

Molecular Partners reports key financials for FY 2018 and corporate highlights for Q4 2018

Molecular Partners announced its unaudited financial results for 2018 and corporate highlights for the fourth quarter 2018. The fourth quarter was marked by positive phase 3 efficacy data presented for abicipar as well as the initiation of a strategic collaboration with Amgen in the field of immuno-…
Show more

Molecular Partners Frequently Asked Questions

  • When was Molecular Partners founded?

    Molecular Partners was founded in 2004.

  • Who are Molecular Partners key executives?

    Molecular Partners's key executives are Michael Tobias Stumpp, Patrick Amstutz and Andreas Emmenegger.

  • How many employees does Molecular Partners have?

    Molecular Partners has 145 employees.

  • Who are Molecular Partners competitors?

    Competitors of Molecular Partners include BioSpecifics Technologies, Abliva and Nordic Nanovector.

  • Where is Molecular Partners headquarters?

    Molecular Partners headquarters is located at 14 Wagistrasse, Zürich-Schlieren.

  • Where are Molecular Partners offices?

    Molecular Partners has offices in Zürich-Schlieren and Cambridge.

  • How many offices does Molecular Partners have?

    Molecular Partners has 2 offices.